Compared with shRNA-NC group, combined silencing of UBB and UBC (shRNA-B4/C2) inhibited 51.51% of tumor volume (Fig. 8C upper panel and Fig. 8D), which was more effectively than that of shRNA-B4-transfected group (27.12%) or shRNA-C2-transfected group (45.05%). The gene discussed is UBB; the disease is neoplasm.